WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) Short Interest Update

Key Points

• Short interest plunged by 82.6% in April to 24,485 shares as of April 15, leaving 0.0% of the float sold short and a days-to-cover ratio of just 0.2 (based on average daily volume of 107,227 shares).
• Shares traded at $8.54 mid-day (down $0.01) on a volume of 32,840 versus an average volume of 63,502, with a 50-day moving average of $9.22, 200-day moving average of $9.11, and a 12-month range of $5.50–$11.21.
• WuXi Biologics is a global CDMO focused on end-to-end biologics services, including development and large-scale manufacturing of monoclonal antibodies, recombinant proteins, and cell and gene therapy vectors.

WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY - Get Free Report) was the target of a significant decrease in short interest in April. As of April 15th, there was short interest totaling 24,485 shares, a decrease of 82.6% from the March 31st total of 140,652 shares. Currently, 0.0% of the company's stock are sold short. Based on an average daily volume of 107,227 shares, the days-to-cover ratio is presently 0.2 days.

WuXi Biologics (Cayman) Price Performance

Shares of OTCMKTS WXXWY traded down $0.01 during mid-day trading on Friday, reaching $8.54. The company had a trading volume of 32,840 shares, compared to its average volume of 63,502. The stock has a fifty day moving average of $9.22 and a two-hundred day moving average of $9.11. WuXi Biologics has a 12-month low of $5.50 and a 12-month high of $11.21.

About WuXi Biologics (Cayman)

WuXi Biologics (Cayman) Inc, trading OTC as WXXWY, is a global contract research, development and manufacturing organization (CDMO) specializing in biologics. Founded as a spin-out from WuXi AppTec and incorporated in the Cayman Islands in 2017, the company offers end-to-end support across the biologics value chain. Its service portfolio encompasses discovery biology, analytical development, process chemistry and large-scale manufacturing for therapeutic proteins and antibodies.

The firm’s core offerings include the development of monoclonal antibodies, recombinant proteins and cell and gene therapy vectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.